Reported 3 days ago
Accuray Incorporated (NASDAQ:ARAY) reported fiscal fourth-quarter revenue of $127.5 million, surpassing expectations of $123.8 million, despite a year-over-year decline. BTIG maintained its Buy rating and raised its price target from $4 to $5, noting that Accuray overcame challenges such as shipping suspensions to China and regional disruptions. The company, known for its CyberKnife technology in cancer treatment, shows potential for growth as management forecasts a positive outlook for fiscal 2026.
Source: YAHOO